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Abstract
Background: Polyploidy is a prominent feature of many human cancers, and it has long been hypothesized that polyploidy
may contribute to tumorigenesis by promoting genomic instability. In this study, we investigated whether polyploidy per se
induced by a relevant oncogene can promote genomic instability and tumorigenicity in human epithelial cells.
Principal Findings: When the oncogenic serine-threonine kinase Pim-1 is overexpressed in immortalized, non-tumorigenic
human prostate and mammary epithelial cells, these cells gradually converted to polyploidy and became tumorigenic. To
assess the contribution of polyploidy to tumorigenicity, we obtained sorted, matched populations of diploid and polyploid
cells expressing equivalent levels of the Pim-1 protein. Spectral karyotyping revealed evidence of emerging numerical and
structural chromosomal abnormalities in polyploid cells, supporting the proposition that polyploidy promotes chromosomal
instability. Polyploid cells displayed an intact p53/p21 pathway, indicating that the viability of polyploid cells in this system
is not dependent on the inactivation of the p53 signaling pathway. Remarkably, only the sorted polyploid cells were
tumorigenic in vitro and in vivo.
Conclusions: Our results support the notion that polyploidy can promote chromosomal instability and the initiation of
tumorigenesis in human epithelial cells.
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Introduction
Aneuploidy is a common characteristic of human cancers and
has been proposed as a driver of tumorigenesis [1,2]. During
tumor initiation, aneuploidy may arise via polyploidization where
unstable tetraploid intermediates cause further chromosomal
abnormalities including chromosomal gains, losses and transloca-
tions [3,4]. In human tumors, aneuploidy is found in pre-
cancerous lesions of the cervix [5–7], head and neck [8], colon
[5,9], esophagus [10] and prostate [11]. Nevertheless, the question
of whether genomic instability is a driving force for cancer
development, or a consequence of tumorigenesis has remained the
subject of debate [12]. A recent study by Fujiwara et al has
provided experimental support for a role for polyploidy in
tumorigenesis by using p53-null tetraploid mouse mammary
epithelial cells [13]. These authors showed that tetraploid cells
generated by transient treatment with a cytokinesis inhibitor,
dihydrocytochalasin B, were tumorigenic in vivo. However, the
impact of aneuploidy on tumorigenicity can be context dependent.
In mice with reduced levels of the mitosis-specific, centromere-
linked motor protein CENP-E, the resulting aneuploidy promotes
tumorigenicity in some tissues while suppressing tumor develop-
ment in others [14]. These findings underscore the importance of
assessing the roles of chromosomal instability in tumorigenesis in
specific cell types and animal species.
In the present study we have examined the question of whether
polyploidy can promote tumorigenesis in human epithelial cells
using a model of spontaneous polyploidy induced by the oncogene
Pim-1. The Pim-1 oncogene is a serine-threonine kinase
implicated in the development of various tumors including
lymphomas and prostate carcinomas [15–17]. We have previously
demonstrated that overexpression of Pim-1 in human prostate and
breast epithelial cells results in the gradual emergence of
polyploidy [18,19]. Notably, Pim-1 is abundantly expressed in
the megakaryocyte lineage where it is involved in the regulation of
polyploidy [20], suggesting that Pim-1 induced polyploidy in
tumorigenesis might be a pathological manifestation of the same
process. As the evolution of polyploidy in Pim-1 expressing cells is
stochastic [19], this allowed us to obtained sorted Pim-1 expressing
cells of the same passage that are either diploid or polyploid based
on their DNA content. Our studies using these cells indicate that
polyploidy induced by Pim-1 can promote the development of
chromosomal abnormalities and tumorigenicity in human prostate
and mammary epithelial cells.
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Polyploid Pim-1-expressing RWPE1 Prostate Cells are
Tumorigenic in Vivo
To examine the oncogenic functions of Pim-1 in prostate
epithelial cells, we stably overexpressed Pim-1 in immortalized,
non-tumorigenic prostate epithelial RWPE1 cells (Figure 1A). As
reported previously [18,19], late passage RWPE1-Pim-1 cells are
polyploid (tetraploid) as shown by FACS for DNA content and
FISH, while early passage cells are diploid (Figures 1B, C). We
injected these cells with matrigel into the flanks of nude mice
subcutaneously to form xenografts. Analysis of the xenograft tissue
indicates that only late passage RWPE1-Pim-1 cells formed small
tumors (40% incidence; n=10, average tumor volu-
me=44.02612.03 mm
3 at time of sacrifice) while both early
and late passage control RWPE1-Neo cells (n=10 each) as well as
early passage RWPE1-Pim-1 cells (n=10) only formed small
benign looking glands (Figure 1D). Thus in this assay, tumorige-
nicity appears to depend on both Pim-1 expression and prolonged
passage and/or polyploidy.
Isolation of Matched Diploid/Polyploid Pim-1-expressing
RWPE1 Cells by Cell Sorting
The results of our xenograft experiments suggested that
polyploidy might have been a contributing factor in the
tumorigenicity of late passage RWPE1-Pim-1 cells, since control
non-polyploid RWPE1-Neo cells of the same late passage as well
as early passage Pim-1-expressing cells were not tumorigenic. To
directly investigate this, we took advantage of the gradual nature
by which polyploidy arises in cultures of Pim-1-expressing cells.
We have previously shown, using three different experimental
approaches that all Pim-1-expressing cells have the potential to
become polyploid, and do so in a stochastic manner [19]. We
sorted intermediate passage cells based on DNA content by FACS
to obtain matched diploid (2N) and polyploid ($4N) cell
populations of the same passage (Figure 2A). After sorting, the
cells stably maintained a diploid or tetraploid profile by FACS.
Importantly, the expression levels of Pim-1 as well as those of
several cell cycle and anti-apoptotic molecules (including Myc,
Cyclin E, Cyclin D2, Bcl-2 and Bcl-XL) were similar in both
diploid and polyploid cells (Figure 2B). Notably, Bcl-2, which is a
known target of Pim-1 [21], is upregulated in RWPE1-Pim-1 cells
relative to control RWPE1-Neo cells; however the sorted RWPE1-
Pim-1 diploid and polyploid cells expressed equivalent levels of
Bcl-2 (Figure 2B). We found no significant differences in the
proliferation rates of diploid and polyploid RWPE1-Pim-1 cells in
vitro (Figure 2C).
Previous studies have suggested the existence of a p53-dependent
checkpoint –the ‘‘tetraploidy checkpoint’’- that limits the prolifer-
ation of polyploid cells, although the existenceof sucha ‘‘tetraploidy
checkpoint’’ has been contested [4,22]. To determine if the p53
signaling pathway is inactivated in the sorted polyploid cells, we
treatedthe cells withthe chemotherapeutic agent daunorubicin.We
observed stabilization of p53 as well as the induction of its target
molecule, p21 after daunorubicin treatment, indicating that the p53
pathway is intact in these cells (Figure 2D). This may appear
Figure 1. Late passage, polyploid, Pim-1-expressing RWPE1 prostate cells are tumorigenic in nude mice. (A) Western blotting for Pim-1
and actin in RWPE1 cells overexpressing Pim-1 or vector control (Neo). Early and late passage cells are shown. (B) Cell cycle profiles of Pim-1
overexpressing RWPE1 cells shows polyploidy in late passage cells. (C) FISH analysis of late passage Pim-1 overexpressing RWPE1 cells using probes
for chromosomes 13 and 21 show chromosome doubling. (D) Sample images of H&E stained sections from RWPE1 xenografts. Only late passage Pim-
1 expressing cells were tumorigenic.
doi:10.1371/journal.pone.0002572.g001
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papillomavirus type 18 (HPV-18) and the E6 protein of HPV-18
is known to interfere with p53 function [23]. Nevertheless, it has
been reported that the p53 pathway is functional in certain HPV-
immortalized cell lines [24], consistent with our results.
Chromosomal Abnormalities in Polyploid RWPE1-Pim-1
Cells
To gain further insight into the genomic alterations in polyploid
cells, we performed karyotype analyses. Spectral karyotyping
(SKY) showed that 100% of the control RWPE1-Neo (n=40) and
diploid RWPE1-Pim-1 cells (n=31) cells examined were near-
diploid, containing between 45 and 50 chromosomes per cell
(Figures 3A, B). By contrast, a majority of the polyploid RWPE1-
Pim-1 cells (81%, n=31) were near-tetraploid, containing 91–100
chromosomes. Apart from whole-chromosomal gains, Pim-1
polyploid cells exhibited a wide range of both numerical and
structural aberrations including chromosomal translocations and
deletions (Figures 3B, C), whereas control Neo and Pim-1 diploid
cells had fewer structural abnormalities and numerical variations.
Although the number of structural chromosomal aberrations per
cell in polyploid cells was approximately twice that in control Neo
or diploid cells, the number of structural chromosomal aberrations
per chromosome was almost the same in all groups (Figure S1),
suggesting that the higher chromosome number in polyploid cells
is a primary factor in the increase in chromosomal abnormalities
observed. Nevertheless, although a majority of polyploid cells
shared the same chromosomal translocation and deletion with
control Neo and diploid cells, attesting to their common origin,
there were also several polyploid cell-specific chromosomal
translocations and deletions present in various fractions of the
polyploid cells (Figure 3C). These results indicate the presence of
chromosomal instability and the emergence of aneuploidy in the
sorted polyploid cells.
Figure 2. Isolation of matched diploid/polyploid RWPE1-Pim-1 cells by cell sorting. (A) Diagram showing scheme for isolation of diploid
(2N) and polyploid (.4N) Pim-1 cells by FACS sorting based on DNA content. Bottom panel is the FACS profile of sorted cells after several passages to
get enough cells for FACS analysis. (B) Western blotting of Pim-1 and other markers in FACS sorted cells shows similar expression levels in sorted
diploid and polyploid cells. (C) Cell counting of diploid and polyploid Pim-1 overexpressing cells. (D) Western blotting shows that the p53 pathway is
intact in all FACS-sorted RWPE1 cells as demonstrated by the induction of p53 and p21 following daunorubicin treatment.
doi:10.1371/journal.pone.0002572.g002
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numerical and structural aberrations from FACS-sorted RWPE1 cells. Total 31 to 40 metaphase spreads were analyzed per sample and scored for the
chromosome number, numerical aberrations, and structural aberrations. (B) Representative SKY images of sorted Neo, diploid and polyploid RWPE1-
Pim-1 cells. Neo: 49,X,del(Y),+5, t(9;20;X),t(11;18),+12,del(12),t(12;21),t(14;18),+15,t(14;18),+20,t(18;20). Diploid: 49,X,del(Y),t(3;4),+5,+5,t(9;20;9),+12,
t(5;12)(12;21),t(14;18),t(7;18),+20,t(17;18;20). Polyploid: 97,XX,del(Y),+1,+1,+1,t(1;5),+2,+2,+3,+3,+3,t(3;7),+4,+4,+5,+5,+5,+5,+5,+5,t(5;21),+6,+6,+7,
+8,+8,+9,+9,t(9;20;9)62,+10,+10,+11,+11,+12,+12,+12,+12,t(5;12)62(12;21)62,+13,+13,+14,+14,t(14;18)62,+15,+15,+16,+16,+17,+17,+18,+18,-
t(7;18)62,+19,+19,+20,+20,+20,+20,t(17;18;20)62,+21,+22. (C) Table showing structural chromosomal aberrations. The numbers of derivative
chromosomes observed are shown. Polyploid-specific abnormalities are shown in bold.
doi:10.1371/journal.pone.0002572.g003
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in Vitro and in Vivo
We next examined the role of polyploidy and the ensuing
chromosomal instability in the in vitro tumorigenicity of RWPE1-
Pim-1 cells by assessing the ability of sorted cells to grow in an
anchorage-independentmannerinsoftagar.AsshowninFigure4A,
only polyploid RWPE1-Pim-1 cells formed colonies in soft agar,
despite the factthattheexpression levelsofPim-1aresimilarinboth
diploid and polyploid cells as noted earlier in Figure 2B and these
cells were carried for the same passage. These data indicate that
Pim-1 expression alone is insufficient to promote growth in soft agar
and that polyploidy (and the resultant genomic instability) can
cooperate with Pim-1 to promote the tumorigenicity of prostate
epithelialcells.Todetermineifgenomicinstabilityduetopolyploidy
can promote tumorigenesis in vivo, we performed tissue recombina-
tion experiments. Human prostate epithelium is known to have the
ability to generate prostate gland-like structures when combined
with rat urogenital mesenchyme (UGM) and implanted under the
renal capsule of immune-deficient mice [25]. We combined the
sorted diploid and polyploid RWPE1-Pim-1 as well as control
RWPE1-Neo cells with UGM and grafted them under the renal
capsule of immune-deficient mice.
Twelve weeks after grafting, all of the grafts from control Neo
(n=4) and diploid cells (n=8) formed largely normal looking,
benign gland structures. However, 3 of 8 grafts from polyploid
cells contained foci of carcinoma in situ (Figure 4B) with evidence
of loss of the basal cell marker p63 and increased levels of mitosis
as shown by staining for phospho-histone H3 (Figure 4B). To
confirm the RWPE1 origin of the glands, human-specific Ku70
staining was used. Taken together, these results indicate that
polyploidy induced by Pim-1 promotes genomic instability which
contributes to tumorigenicity.
Polyploid, Pim-1-expressing Telomerase-Immortalized
Mammary Epithelial Cells are Tumorigenic
We next sought to determine if the role of Pim-1-induced
polyploidy in promoting genomic instability and tumorigenicity
extends to other human cell types. In addition, we wanted to
examine this phenomenon in cells immortalized through means
other than an oncogenic virus (i.e. HPV). We used hTERT-
HME1 cells which are non-tumorigenic human mammary
epithelial cells immortalized by expression of the human
telomerase catalytic subunit, hTERT. Similar to our findings with
the RWPE1 prostate cells, we observed that only polyploid, late
passage Pim-1 expressing hTERT-HME1 cells formed colonies in
soft agar (Figure S2). Next, we isolated matched diploid/polyploid
Pim-1-expressing hTERT-HME1 cells of the same passage by cell
sorting. The FACS profile of sorted cells showed that Pim-1
diploid and control Neo derived-cells maintained diploid DNA
content, whereas Pim-1 polyploid cells were almost exclusively
tetraploid (Figure 5A). The expression levels of Pim-1 as well as
Myc were comparable in both the diploid and polyploid hTERT-
HME1 cells (Figure 5B). We observed a modest increase in Cyclin
E in the polyploid cells, which may be related to the increased
proliferation rate of the hTERT-HME1-derived polyploid cells in
vitro (Figure 5C). This contrasts with the case for RWPE1-derived
polyploid cells which displayed comparable proliferation rate
relative to their diploid counterparts. Furthermore, we examined
the expression of various cell markers in polyploid cells including
early progenitor cell markers CD44, nestin and cytokeratin 5 by
immunofluorescence. We found no significant differences between
diploid and polyploid cells (Figure S3). We also probed the p53
pathway in hTERT-HME1-derived polyploid cells by treating the
cells with daunorubicin followed by western blotting for p53 and
p21. The results indicate that as in the polyploid RWPE1-derived
cells this pathway is intact in the hTERT-HME1 cells (Figure 5D).
Thus the viability of the polyploid cells examined here does not
appear to depend on the inactivation of p53. Since Pim-1 has pro-
survival functions, it may substitute for p53 loss in promoting the
viability of emerging polyploid cells.
Chromosomal Abnormalities in Polyploid hTERT-HME1
Cells
The karyotypes of control Neo and diploid Pim-1-hTERT-
HME1 cells were stable and uniform with few numerical and
structural abnormalities (Figure 6). All of the Neo control cells
examined (n=40) and almost all of the diploid Pim-1 cells (39 of
40) were diploid or near-diploid, containing between 45 and 48
chromosomes. In contrast, all polyploid cells (n=13) contained 79
to 89 chromosomal numbers, indicative of near-tetraploidy
(Figure 6A). The observed chromosome numbers in the polyploid
cells (79–89 chromosomes) are lower than the predicted doubling
of the number of chromosomes in the Neo/Diploid cells (90–98
chromosomes). This suggests that sub-tetraploid cell population
could be derived either from tetraploid cells by ongoing
chromosomal loss, or from the diploid population by unknown
mechanisms. Furthermore, the polyploid cells displayed signifi-
cantly more structural chromosomal abnormalities than the
control cells (Figures 6A–C). To gain additional insights into the
evolution of tumorigenic subpopulations among polyploid cells, we
isolated and cultured cells from soft agar colonies derived from
polyploid cells [see Figure 7A below]. By SKY analysis, soft agar-
derived cells displayed increased numerical and structural
aberrations similar to the polyploid cells (Figures 6A–C). In
addition, the numbers of structural chromosomal aberrations per
chromosome were higher in the polyploid and soft agar-derived
cells compared to the control Neo or diploid cells (Figure S1).
These results suggest that the chromosomal abnormalities seen in
these cells are not merely due to increased chromosomal numbers
but are due to active chromosomal instability. Notably, 7 out of 25
of the soft agar-derived cells examined contained a unique
chromosomal translocation, t(8;20), providing further evidence of
chromosomal instability in the evolution of tumorigenic popula-
tions (Figure 6C).
Sorted, Polyploid hTERT-HME1 Mammary Cells are
Tumorigenic
The tumorigenicity of the sorted hTERT-HME1 cells was
tested by anchorage-independent growth in soft agar. Polyploid
cells formed robust colonies in soft agar (Figure 7A), unlike the
diploid or Neo control cells, indicating that the pro-tumorigenic
effect of Pim-1-induced polyploidy extends to different cell types.
Furthermore, the soft agar derived cells formed larger sized
colonies with higher frequency than polyploid cells, suggesting
more tumorigenic potential of these cells (Figure 7B).
Discussion
In this study we demonstrated that polyploidy, induced by the
oncogenic kinase Pim-1 can promote the development of
aneuploidy and tumorigenicity in human epithelial cells. Using
genetically matched FACS-sorted diploid and polyploid prostate
and mammary epithelial cells, we demonstrated that only the
polyploid cells were tumorigenic despite the fact that they
expressed equivalent levels of the Pim-1 oncogene. Thus, Pim-1
overexpression itself in the absence of polyploidy is not sufficient
for tumorigenicity in our experimental system. We also provide
Polyploidy in Tumorigenesis
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2572evidence that the tumorigenicity of polyploid cells is likely due to
the intrinsic chromosomal instability present in these cells
including whole-chromosome gains/losses as well as structural
abnormalities including deletions and translocation. Furthermore,
our data demonstrated that the survival of polyploid cells is not
dependent on inactivation of the p53 pathway, suggesting that
Pim-1 might substitute for p53 loss.
Genomic instability is a hallmark of human cancer and a
majority of carcinomas display gross chromosomal abnormalities.
It is thought that polyploidization (specifically tetraploidy) may
Figure 4. Polyploidy promotes the tumorigenicity of RWPE1 prostate cells in vitro and in vivo. (A) Soft agar assay with colony counting in
FACS-sorted RWPE1 cells. Colonies larger than 0.5 mm in diameter were counted. Results represent average of triplicate experiments. *p,0.05. (B)
Histological analysis of grafts of diploid and polyploid RWPE1-Pim-1 cells recombined with rat UGM and grafted under the kidney capsule. Grafts from
polyploid cells contained foci of carcinoma-in-situ with loss of the basal cell marker p63 and high rates of mitotic cells (p-HH3, phospho-histone H3)
while diploid cells formed largely small benign looking glands that express p63 and low rates of mitosis (p-HH3). A human-specific Ku70 antibody was
used to confirm the human origin of glands. All images were taken at the same magnification of 46.
doi:10.1371/journal.pone.0002572.g004
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ability to catalyze the development of additional chromosomal
abnormalities due to segregation errors that result from having
multiple centrosomes and extra chromosomes [3,26]. The diverse
chromosomal landscape of the resulting cells may then provide a
permissive substrate on which selective forces can act to mould the
development of a tumor. In prostate cancer, abnormal diploid
cancers may represent an early stage in ploidy progression and
DNA ploidy abnormalities occur in benign prostatic tissue
adjacent to many prostate cancers [27,28]. In breast cancer, there
is also a correlation between aneuploidy and tumor progression
[29–31]. However, despite the correlation between aneuploidy
and tumorigenicity, direct tests for the role of aneuploidy in tumor
development have been difficult partly due to the lack of suitable
experimental systems, especially those consisting of human cells.
One of the more direct tests of the role of tetraploidy in promoting
tumorigenicity relied on chemical treatment with a cytokinesis
inhibitor, dihydrocytochalasin B (DCB), to induce tetraploidy in
p53-null mouse mammary epithelial cells (MMECs) [13]. In this
study, the authors demonstrated that tetraploidy can promote
chromosomal instability and tumorigenesis. Our data are
consistent with this conclusion. However our system differs in
several respects from the MMEC model: (i) We employed human
epithelial cells, which are difficult to transform [32,33]. (ii) The
development of polyploidy in our system is spontaneous, following
the expression of an oncogene, Pim-1. As many cancer-related
genes have been linked to the development of polyploidy, for
example MYC [34], APC [35,36], Pim-1 [18,19], BRCA2 [37],
and Aurora-A [38], our model may reflect an actual pathway for
tumor initiation. (iii) In our system, polyploid cells arise in the face
of an intact p53 pathway, whereas p53
+/+ tetraploid MMECs did
not survive [13]. It has been reported that p53 loss facilitates the
formation of tetraploidy and the survival of cells with genomic
instability [39,40].
Some studies posit the existence of a p53-dependent checkpoint
that prevents the propagation of tetraploid cells [41], while other
studies have questioned the existence of such a ‘‘tetraploidy
checkpoint’’ [4,22]. Nevertheless, tetraploid cells appear to be
generally less fit than diploid cells. For example tetraploid cells are
reported to have an elevated rate of spontaneous apoptosis that is
dependent on p53 expression [42]. Importantly, Pim-1 has been
reported to enhance cell survival through upregulation of Bcl-2
Figure 5. FACS sorted, Polyploid, Pim-1 expressing telomerase-immortalized mammary epithelial cells (hTERT-HME1) are
tumorigenic in vitro. (A) FACS profile after cell sorting. hTERT-HME1 cells were sorted based on DNA content. (B) Western blotting of Pim-1 and
other markers in sorted cells. Pim-1 expression levels are similar in diploid and polyploid cells. (C) Cell counting of Neo control, diploid and polyploid
Pim-1 overexpressing cells. (D) Western blotting for p21 and p53 after daunorubicin treatment shows that p53 function is intact in all FACS-sorted
hTERT-HME1 cells.
doi:10.1371/journal.pone.0002572.g005
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phosphorylation [43]. Therefore, it is possible that Pim-1, with its
pro-survival functions, substitutes for p53 loss to allow for the
survival of polyploid cells in our system.
Further analyses of polyploid cells before and after tumor
formation are required to gain additional insights into the
promotion of tumorigenesis by polyploidy. Nevertheless, it is
interesting to note that the aneuploidy hypothesis predicts long
latency for tumorigenesis as well as clonality. If the driving force
for tumorigenesis is the inherent aneuploid karyotype initiated by a
carcinogen or arising spontaneously, the resulting chromosomal
instability will promote the appearance of preneoplastic and
eventually neoplastic karyotypes. The generation of a neoplastic
cell species will be expected to be slow and thus clonal [26,44].
Tumorigenicity induced by polyploidy may also follow divergent
routes depending on the particular karyotype generated. Consis-
tent with this notion, the polyploid prostate and mammary
epithelial cells we generated displayed very distinctive karyotypes
although both cells were tumorigenic. They displayed some
phenotypic differences as well. The RWPE-Pim-1 polyploid cells
Figure 6. Chromosomal abnormalities in polyploid hTERT-HME1 cells. (A) Percentage of cells showing total chromosome number,
numerical and structural aberrations from FACS-sorted hTERT-HME1 cells. Note that karyotypes of polyploid and soft agar derived cells are highly
heterogeneous, whereas karyotypes of control Neo and diploid cells are more uniform. Total 13 to 40 metaphase spreads were analyzed per sample
and scored for the chromosome number, numerical aberrations, and structural aberrations. (B) Representative SKY images from each FACS-sorted
hTERT-HME1 cells. Neo: 45,XX,t(6;17),217. Diploid: 46,XX,del(5),t(5;8). Polyploid: 89,XXXX,+1,+1,t(1;2),+2,+3,+3,+4,+5,+5,+5,
del(5),+6,+6,+7,+7,+8,+8,+9,+9,+10,+10,+11,+11,del(11),+12,+12,+13,+13,+14,+15,+15,+16,+16,+17,+17,t(15;17),+18,+18,+19,+19,+20,+20,+21,+21,+22.
Soft agar: 89,XXX,+1,+1,t(1;2),+2,+3,+3,+4,+5,+5,+5,del(5), +6,+6,+7,+7,+8,+8,+8,t(8;20),+9,+9,+10,+10,+11,+11,del(11),+12,+12,+13,+13,+14,
+14,+15,+16,+16,+17,+17,+18,+18,+19,+19,+20,+21,+21,+22,+22. (C) Tables showing derivative chromosomes in the different sorted cell types. The
numbers of derivative chromosomes observed are shown. Polyploid and soft agar derived cell-specific abnormalities are shown in bold.
doi:10.1371/journal.pone.0002572.g006
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counterparts while hTERT-HME1-Pim-1 polyploid cells prolifer-
ated at a much faster rate than the diploid cells.
In summary, our results provide evidence that polyploidy, by
promoting the development of aneuploidy, is a promoter of
tumorigenesis in human cells. This fact, coupled with the
observation that many human tumors exhibit polyploidy, make
polyploid cells attractive targets for novel therapeutics.
Materials and Methods
Cells, Animals, and Reagents
RWPE1 prostate and hTERT-HME1 mammary cell lines stably
expressing Pim-1 were generated as described [18,19]. Early,
middle and late passage cellsaredefined based ontheappearanceof
polyploidy upon in vitro culture as described previously [19]; early
passage 1–20; middle passage 25–40; late passage .40. Six to eight
week old athymic nude mice, male severe combined immunode-
ficient (SCID) mice [C.B.17/IcrHsd-scid], and pregnant Sprague-
Dawley rats were obtained from NCI-Fredrick, The Jackson
Laboratory or Harlan Laboratory, respectively. Antibodies used
for western blotting include anti-Pim-1 (12H8), Myc (9E10), Cyclin
E (M-20), Cyclin D2 (C-17), Bcl-2 (100), Bcl-XL (H-5), p53 (DO-1),
p21 (F-5) and actin (C-11) (all from Santa Cruz Biotechnology).
Antibodies against p63 (PPM 201 AA, H, Biocare Medical),
phospho-histone H3 S10 (06-570, Upstate), and Ku 70 (as10878,
abcam) were used for immunostaining.
Flow Cytometric Analysis
Cells were fixed with 70–100% cold ethanol and DNA was
stained with propidium iodide for analysis as described [18,19].
Sorting of cells based on DNA content was performed as described
[19]. Briefly, intermediate passage (passage 25) cells were stained
with 5 ug/ml of Hoechst 33342 (Sigma-Aldrich) for 90 min at
37uC and sorted according to DNA content (2N, 4N, and .4N)
using a cell sorter. Diploid (2N DNA) and polyploid (.4N DNA)
cells were used for our experiments. 4N DNA cells were not used
since this is the mixed population of G2/M phase of 2N DNA cells
and G1 phase of .4N DNA cells.
Western Blotting and Immunohistochemistry
For western blot analysis, total cell lysates and samples were
prepared and processed as described [18,19] with the indicated
antibodies. For daunorubicin treatment, both RWPE-1 or
hTERT-HME1 cells were treated with 0.5 mm daunorubicin
(Sigma-Aldrich, D8809) for 6 and 24 h, and total cell lysates were
prepared for western blotting. Immunohistochemistry was carried
out as previously described [45].
Soft Agar Assays
These were carried out as described [46]. Briefly, 10
4 cells were
mixed with 0.3% soft agar and plated on top of 0.6% bottom agar
seeded on each of a 60 mm plate. Triplicate plating was carried
out for each sample. The cells were incubated at 37uC for 2 weeks
to allow colony formation, and stained with 0.05% crystal violet
for colony counting. Images were captured with a Leica DM IRB
inverted wide field microscope with a Nikon DXM1200C camera.
Xenograft and Tissue Recombination Assays
For xenografts, 3610
6 RWPE1 cells were mixed with 400 mlo f
matrigel and injected into 6–8 week old athymic nude mice
subcutaneously. Mice were sacrificed after 8 months for
histological analysis. Tumor size was measured with calipers and
the histology of all samples was examined after sacrifice. For tissue
recombination, 10
5 sorted RWPE1-Pim-1 as well as control
RWPE1-Neo cells were recombined with 2.5610
5 rat urogenital
Figure 7. Polyploidy promotes the tumorigenicity of hTERT-HME1 cells. Soft agar assay of FACS-sorted diploid and polyploid hTERT-HME1
Pim-1 overexpressing cells and control Neo cells. Note the larger colonies in polyploid cells. Colonies larger than 1 mm in diameter were counted
from triplicate of 60 mm dishes. Original magnification: 106. (B) We isolated cells from soft agar colonies formed by polyploid cells shown in Fig. 7A.
The tumorigenic potential of these soft agar-derived polyploid cells was compared side by side with that of the parental polyploid cells by soft agar
assay. The soft agar-derived cells formed larger size colonies with higher frequency than the parental polyploid cell population. Original
magnification; 46.
doi:10.1371/journal.pone.0002572.g007
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graft). Rat collagen was prepared as described previously [25].
Briefly, tails from mature rats were taken and soaked in 70%
ethanol, and then the skin was split at the tail root and peeled
away. The tails were cut away and each tendon was teased to
separate the fiber. Then tendons were transferred to acetic acid,
centrifuge, and stored at 4uC until use. Rat UGM was prepared
from 18-day embryonic fetuses. Urogenital sinuses were dissected
from fetuses and separated into epithelial and mesenchymal
components by tryptic digestion as described previously [25].
Single cells of UGM were then prepared by a 90-min digestion at
37uC with 187 units/ml collagenase (Gibco-BRL). The recombi-
nants were incubated overnight in a 5% CO2 humidified
incubator at 37uC in RPMI1640 and subsequently placed beneath
the renal capsule of male athymic mice. Testosterone pellets were
implanted dorsally under the skin of SCID mice. 12 weeks after
grafting, the hosts were sacrificed. Harvested grafts were fixed in
paraffin and embedded for histological and immunohistochemical
analysis as described [45]. Experiments were performed according
to the protocols approved by the Institutional Animal Care and
Use Committees at the University of Alabama at Birmingham and
at Vanderbilt University.
Fluorescence in situ hybridization (FISH) and Spectral
Karyotyping (SKY)
For FISH, cells were prepared and processed as described [14].
SKY analysis was done as described [47] and was carried out at
the Roswell Park Cancer Institute SKY Analysis Facility. Briefly,
the metaphase chromosomes were prepared by treatment cells
with either Colcemid at 0.06 mg/ml or Nocodazole at 0.5 mg/ml
for 2–4 hr. The SKY-DAPI images were captured using a Nikon
microscope equipped with a Spectral cube and Interferometer
module. Spectral karyotypes were prepared using SKY View
software (Version 1.62). Numerical chromosomal abnormalities
were determined based on the deviation from 46 (for diploid cells)
or 92 (for tetraploid cells) chromosomes per cell.
Supporting Information
Methods S1 Immunofluorescence methods for Figure S3.
Found at: doi:10.1371/journal.pone.0002572.s001 (0.03 MB
DOC)
Figure S1 The relationship of chromosomal abnormalities to the
number of chromosomes. The number of structural chromosomal
aberrations per cell or per chromosome was plotted with the data
presented in Figure 3 (RWPE1 cells) and Figure 6 (hTERT-
HME1 cells).
Found at: doi:10.1371/journal.pone.0002572.s002 (1.04 MB TIF)
Figure S2 Late passage, polyploid, Pim-1 expressing hTERT-
HME1 cells are tumorigenic in vitro. (A) Western blot for Pim-1 in
early and late passage human telomerase immortalized mammary
epithelial (hTERT-HME1) cells stably expressing Pim-1. (B) Cell
cycle profile of Pim-1 overexpressing hTERT-HME1 cells. (C)
Soft agar assay of hTERT-HME1-Pim-1 cells. (D) Soft agar
colonies larger than 1 mm in diameter were counted from 60 mm
dishes. The data represent the average from triplicate experiments.
*p,0.05.
Found at: doi:10.1371/journal.pone.0002572.s003 (1.76 MB TIF)
Figure S3 Expression of cell markers in sorted diploid and
polyploid-hTERT-HME1 cells. Expression level for CD44,
cytokeratin 5, and nestin were examined by immunofluorescence
in diploid and polyploid hTERT-HME1 cells. There are no
significant differences between these two cells. Inset, higher
magnification image of nestin stain.
Found at: doi:10.1371/journal.pone.0002572.s004 (2.87 MB TIF)
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